

**COMPLETE LIST OF CLAIMS**

**Claims 1-14 (cancelled)**

**Claim 15 (amended):** A therapeutic composition for the symptomatic relief of cough associated with respiratory tract conditions resulting from the common cold, bronchial asthma, and acute and chronic bronchitis, in warm-blooded animals in need of such treatment, said composition comprising in tablet form ~~pharmaceutically effective amounts of~~ active ingredients and a pharmaceutically suitable carrier, said active ingredients consisting of carbetapentane tannate in an amount of from about 50 mg. to about 75 mg., per tablet, and guaifenesin in an amount of from about 100 mg. to about 300 mg., per tablet.

**Claim 16 (previously-presented):** The therapeutic composition of claim 15, wherein said tablet contains about 60 mg. of carbetapentane tannate, per tablet, and about 200 mg. of guaifenesin, per tablet.

**Claim 17 (amended):** A therapeutic composition for the symptomatic relief of cough associated with respiratory tract conditions resulting from the common cold, bronchial asthma, and acute and chronic bronchitis, in warm-blooded animals in need of such treatment, said composition comprising ~~a pharmaceutically effective amount of~~ active ingredients suspended in a pharmaceutically suitable liquid carrier, said active ingredients consisting of carbetapentane tannate in an amount of from about 20 mg. to about 40 mg., per 5 ml. of suspension, and guaifenesin in an amount of from about 50 mg. to about 150 mg., per 5 ml. of suspension.

Claim 18 (**previously-presented**): The therapeutic composition of claim 17, wherein said suspension contains about 30 mg. of carbetapentane tannate, per 5 ml. of suspension, and about 100 mg. of guaifenesin, per 5 ml. of suspension.

Claim 19 (**amended**): A method for symptomatically treating and relieving the distress of cough associated with respiratory tract conditions resulting from the common cold, bronchial asthma, and acute and chronic bronchitis, in warm-blooded animals which comprises orally administering to warm-blooded animals in need of such treatment ~~a therapeutic amount of a~~ composition comprising in tablet form ~~pharmaceutically effective amounts of~~ active ingredients and a pharmaceutically suitable carrier, said active ingredients consisting of carbetapentane tannate in an amount of from about 50 mg. to about 75 mg., per tablet, and guaifenesin in an amount of about 100 mg. to about 300 mg. ~~guaifenesin~~, per tablet.

Claim 20 (**amended**): The method of claim 19 wherein said ~~tablets contain~~ tablet contains about 60 mg. of carbetapentane tannate, per tablet, and about 200 mg. of guaifenesin, per tablet.

Claim 21 (**amended**): A method for symptomatically treating and relieving the distress of cough associated with respiratory tract conditions resulting from the common cold, bronchial asthma, and acute and chronic bronchitis, in warm-blooded animals which comprises orally administering to warm-blooded animals in need of such treatment ~~a therapeutic amount of a~~ composition comprising ~~a pharmaceutically effective amount of~~ active ingredients suspended in a pharmaceutically suitable liquid carrier, said active ingredients consisting of carbetapentane tannate in an amount of from about 20 mg. to about 40 mg., per 5 ml. of suspension, and

guaifenesin in an amount of from about 50 mg. to about 150 mg., per 5 ml. of suspension.

Claim 22 (**amended**): The method of claim 21 wherein said suspension ~~form~~ contains about 30 mg. of carbetapentane tannate, per 5 ml. of suspension, and about 100 mg. of guaifenesin, per 5 ml. of suspension.

Claims 23-30 (**cancelled**)

Claim 31 (**new**): The method of claim 19, wherein said tablet is administered twice-a-day.

Claim 32 (**new**): The method of claim 20, wherein said tablet is administered twice-a-day.

Claim 33 (**new**): The method of claim 21, wherein said suspension is administered twice-a-day.

Claim 34 (**new**): The method of claim 22, wherein said suspension is administered twice-a-day.